The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
For more information about the trial above please contact the study team:
Principal Investigator, Frank Brescia, at firstname.lastname@example.org.
Study Coordinator, Alexandria Green, at email@example.com.
Trial opened at the following institutions: Beaufort Memorial Hospital, Medical University of South Carolina, Tidelands Health